Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) EBITDA Margin (2022 - 2025)

Arcutis Biotherapeutics has reported EBITDA Margin over the past 4 years, most recently at 13.87% for Q4 2025.

  • Quarterly results put EBITDA Margin at 13.87% for Q4 2025, up 3021.0% from a year ago — trailing twelve months through Dec 2025 was 4.37% (up 6762.0% YoY), and the annual figure for FY2025 was 4.35%, up 7974.0%.
  • EBITDA Margin for Q4 2025 was 13.87% at Arcutis Biotherapeutics, up from 7.44% in the prior quarter.
  • Over the last five years, EBITDA Margin for ARQT hit a ceiling of 13.87% in Q4 2025 and a floor of 14903.86% in Q3 2022.
  • Median EBITDA Margin over the past 4 years was 119.91% (2023), compared with a mean of 1611.75%.
  • Biggest five-year swings in EBITDA Margin: surged 1475501bps in 2023 and later surged 3021bps in 2025.
  • Arcutis Biotherapeutics' EBITDA Margin stood at 2415.03% in 2022, then soared by 80bps to 488.66% in 2023, then soared by 97bps to 16.33% in 2024, then soared by 185bps to 13.87% in 2025.
  • The last three reported values for EBITDA Margin were 13.87% (Q4 2025), 7.44% (Q3 2025), and 19.36% (Q2 2025) per Business Quant data.